Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Obesity Reports
Published in: Current Obesity Reports 3/2016

01-09-2016 | The Obesity Epidemic: Causes and Consequences (A Peeters and A Cameron, Section Editors)

Infectious and Environmental Influences on the Obesity Epidemic

Authors: Lili Huo, Jasmine Lyons, Dianna J. Magliano

Published in: Current Obesity Reports | Issue 3/2016

Login to get access

Abstract

Over the last two decades, the prevalence of obesity has increased rapidly. While it is intuitively appealing to believe that the causes of obesity are manifestly related to excess dietary intake, combined with a reduced expenditure of energy via a decrease in physical activity, it is also been noted that the evidence for these as the sole causes of the obesity epidemic is incomplete. This has led to the search for other causes of obesity, particularly those which stem from the environment we live in. This review will explore two putative causes of obesity: infections and environmental pollutants. It will focus on the key human infection associated with obesity—human adenovirus 36 (Ad36) and will discuss several environmental pollutants which have been postulated to be involved in the development of obesity: bisphenol A, phthalates and persistent organic pollutants. For each of these, the epidemiology and biological mechanisms underpinning the association of these agents with obesity will be reviewed.
Literature
1.•
McAllister EJ, Dhurandhar NV, Keith SW, et al. Ten putative contributors to the obesity epidemic. Crit Rev Food Sci Nutr. 2009;49(10):868–913. This publication provides the premise for this review and demonstrates that there may be other important risk factors for obesity, independent of increased caloric intake and decreased physical activity.CrossRefPubMedPubMedCentral
2.
Lyons MJ, Faust IM, Hemmes RB, et al. A virally induced obesity syndrome in mice. Science. 1982;216(4541):82–5.CrossRefPubMed
3.
4.
Lynch 3rd JP, Fishbein M, Echavarria M. Adenovirus. Semin Respir Crit Care Med. 2011;32(4):494–511.CrossRefPubMed
5.
Dhurandhar NV. A framework for identification of infections that contribute to human obesity. Lancet Infect Dis. 2011;11(12):963–9.CrossRefPubMed
6.
Atkinson RL, Dhurandhar NV, Allison DB, et al. Human adenovirus-36 is associated with increased body weight and paradoxical reduction of serum lipids. Int J Obes (Lond). 2005;29(3):281–6.CrossRef
7.
Trovato GM, Castro A, Tonzuso A, et al. Human obesity relationship with Ad36 adenovirus and insulin resistance. Int J Obes (Lond). 2009;33(12):1402–9.CrossRef
8.
Atkinson RL, Lee I, Shin HJ, He J. Human adenovirus-36 antibody status is associated with obesity in children. Int J Pediatr Obes. 2010;5(2):157–60.CrossRefPubMed
9.
Na HN, Hong YM, Kim J, et al. Association between human adenovirus-36 and lipid disorders in Korean schoolchildren. Int J Obes (Lond). 2010;34(1):89–93.CrossRef
10.
Gabbert C, Donohue M, Arnold J, Schwimmer JB. Adenovirus 36 and obesity in children and adolescents. Pediatrics. 2010;126(4):721–6.CrossRefPubMed
11.
Lin WY, Dubuisson O, Rubicz R, et al. Long-term changes in adiposity and glycemic control are associated with past adenovirus infection. Diabetes Care. 2012
12.
Sabin MA, Burgner D, Atkinson RL, et al. Longitudinal investigation of adenovirus 36 seropositivity and human obesity: the Cardiovascular Risk in Young Finns Study. Int J Obes (Lond). 2015;39(11):1644–50.
13.
Na HN, Kim J, Lee HS, et al. Association of human adenovirus-36 in overweight Korean adults. Int J Obes (Lond). 2012;36(2):281–5.CrossRef
14.
Goossens VJ, deJager SA, Grauls GE, et al. Lack of evidence for the role of human adenovirus-36 in obesity in a European cohort. Obesity (Silver Spring). 2011;19(1):220–1.CrossRef
15.
Raben A, Haulrik N, NV D. Minor role of human adenovirus-36 in the obesity epidemic in Denmark. Int J Obes Rev. 2001;25(Suppl):S46.
16.
Broderick MP, Hansen CJ, Irvine M, et al. Adenovirus 36 seropositivity is strongly associated with race and gender, but not obesity, among US military personnel. Int J Obes (Lond). 2010;34(2):302–8.CrossRef
17.
Yamada T, Hara K, Kadowaki T. Association of adenovirus 36 infection with obesity and metabolic markers in humans: a meta-analysis of observational studies. PLoS One. 2012;7(7), e42031.CrossRefPubMedPubMedCentral
18.•
Shang Q, Wang H, Song Y, et al. Serological data analyses show that adenovirus 36 infection is associated with obesity: a meta-analysis involving 5739 subjects. Obesity (Silver Spring). 2014;22(3):895–900. Evidence showing the Ad36 infection is related to obesity in children.CrossRef
19.
Waye MM. New insights into how adenovirus might lead to obesity: an oxidative stress theory. Free Radic Res. 2011;45(8):880–7.CrossRefPubMed
20.
Na HN, Kim H, Nam JH. Novel genes and cellular pathways related to infection with adenovirus-36 as an obesity agent in human mesenchymal stem cells. Int J Obes (Lond). 2012;36(2):195–200.CrossRef
21.
Carson R. Silent spring. Boston, Massachusetts: Houghton Mifflin; 1962.
22.
Baillie-Hamilton PF. Chemical toxins: a hypothesis to explain the global obesity epidemic. J Altern Complement Med. 2002;8(2):185–92.CrossRefPubMed
23.
Regnier SM, Sargis RM. Adipocytes under assault: environmental disruption of adipose physiology. Biochim Biophys Acta. 2014;1842(3):520–33.CrossRefPubMed
24.
25.
Burridge E. Bisphenol A: product profile. Eur Chem News 2003; 17
26.
Geens T, Aerts D, Berthot C, et al. A review of dietary and non-dietary exposure to bisphenol-A. Food Chem Toxicol. 2012;50(10):3725–40.CrossRefPubMed
27.
Vandenberg LN, Chahoud I, Heindel JJ, et al. Urinary, circulating, and tissue biomonitoring studies indicate widespread exposure to bisphenol A. Environ Health Perspect. 2010;118(8):1055–70.CrossRefPubMedPubMedCentral
28.
Rancière F, Lyons JG, Loh VH, et al. Bisphenol A and the risk of cardiometabolic disorders: a systematic review with meta-analysis of the epidemiological evidence. Environ Health 2015; 14(46):14–46.
29.
Oppeneer SJ, Robien K. Bisphenol A exposure and associations with obesity among adults: a critical review. Public Health Nutr. 2015;18(10):1847–63.CrossRefPubMed
30.
Fernandez MF, Arrebola JP, Taoufiki J, et al. Bisphenol-A and chlorinated derivatives in adipose tissue of women. Reprod Toxicol. 2007;24(2):259–64.CrossRefPubMed
31.
Nikaido Y, Danbara N, Tsujita-Kyutoku M, et al. Effects of prepubertal exposure to xenoestrogen on development of estrogen target organs in female CD-1 mice. In Vivo. 2005;19(3):487–94.PubMed
32.
Newbold RR. Impact of environmental endocrine disrupting chemicals on the development of obesity. Hormones (Athens). 2010;9(3):206–17.CrossRef
33.
34.
Masuno H, Iwanami J, Kidani T, et al. Bisphenol a accelerates terminal differentiation of 3T3-L1 cells into adipocytes through the phosphatidylinositol 3-kinase pathway. Toxicol Sci. 2005;84(2):319–27.CrossRefPubMed
35.
Ben-Jonathan N, Hugo ER, Brandebourg TD. Effects of bisphenol A on adipokine release from human adipose tissue: implications for the metabolic syndrome. Mol Cell Endocrinol. 2009;304(1–2):49–54.CrossRefPubMedPubMedCentral
36.
Anderson OS, Peterson KE, Sanchez BN, et al. Perinatal bisphenol A exposure promotes hyperactivity, lean body composition, and hormonal responses across the murine life course. FASEB J. 2013;27(4):1784–92.CrossRefPubMedPubMedCentral
37.
38.
Desvergne B, Feige JN, Casals-Casas C. PPAR-mediated activity of phthalates: a link to the obesity epidemic? Mol Cell Endocrinol. 2009;304(1–2):43–8.CrossRefPubMed
39.
Kuo CC, Moon K, Thayer KA, Navas-Acien A. Environmental chemicals and type 2 diabetes: an updated systematic review of the epidemiologic evidence. Curr Diab Rep. 2013;13(6):831–49.CrossRefPubMedPubMedCentral
40.
Goodman M, Lakind JS, Mattison DR. Do phthalates act as obesogens in humans? A systematic review of the epidemiological literature. Crit Rev Toxicol. 2014;44(2):151–75.CrossRefPubMed
41.
Lind L, Lind PM. Can persistent organic pollutants and plastic-associated chemicals cause cardiovascular disease? J Intern Med. 2012;271(6):537–53.CrossRefPubMed
42.
Hatch EE, Nelson JW, Qureshi MM, et al. Association of urinary phthalate metabolite concentrations with body mass index and waist circumference: a cross-sectional study of NHANES data, 1999–2002. Environ Health. 2008;7:27.CrossRefPubMedPubMedCentral
43.
Stahlhut RW, van Wijngaarden E, Dye TD, et al. Concentrations of urinary phthalate metabolites are associated with increased waist circumference and insulin resistance in adult U.S. males. Environ Health Perspect. 2007;115(6):876–82.CrossRefPubMedPubMedCentral
44.•
Lind PM, Roos V, Ronn M, et al. Serum concentrations of phthalate metabolites are related to abdominal fat distribution two years later in elderly women. Environ Health. 2012;11:21. First prospective data showing independent links of phthalate exposure to fat distribution.CrossRefPubMedPubMedCentral
45.
Wang HX, Zhou Y, Tang CX, et al. Association between bisphenol A exposure and body mass index in Chinese school children: a cross-sectional study. Environ Health. 2012;11:79.CrossRefPubMedPubMedCentral
46.
Teitelbaum SL, Mervish N, Moshier EL, et al. Associations between phthalate metabolite urinary concentrations and body size measures in New York City children. Environ Res. 2012;112:186–93.CrossRefPubMedPubMedCentral
47.
Boas M, Frederiksen H, Feldt-Rasmussen U, et al. Childhood exposure to phthalates: associations with thyroid function, insulin-like growth factor I, and growth. Environ Health Perspect. 2010;118(10):1458–64.CrossRefPubMedPubMedCentral
48.
Hao C, Cheng X, Xia H, Ma X. The endocrine disruptor mono-(2-ethylhexyl) phthalate promotes adipocyte differentiation and induces obesity in mice. Biosci Rep. 2012;32(6):619–29.CrossRefPubMedPubMedCentral
49.
50.
Heindel JJ, Newbold R, Schug TT. Endocrine disruptors and obesity. Nat Rev Endocrinol. 2015;11(11):653–61.CrossRefPubMed
51.
Lee DH, Porta M, Jacobs Jr DR, Vandenberg LN. Chlorinated persistent organic pollutants, obesity, and type 2 diabetes. Endocr Rev. 2014;35(4):557–601.CrossRefPubMed
52.
Tang-Peronard JL, Andersen HR, Jensen TK, Heitmann BL. Endocrine-disrupting chemicals and obesity development in humans: a review. Obes Rev. 2011;12(8):622–36.CrossRefPubMed
53.
Blanck HM, Marcus M, Rubin C, et al. Growth in girls exposed in utero and postnatally to polybrominated biphenyls and polychlorinated biphenyls. Epidemiology. 2002;13(2):205–10.CrossRefPubMed
54.
Erkin-Cakmak A, Harley KG, Chevrier J, et al. In utero and childhood polybrominated diphenyl ether exposures and body mass at age 7 years: the CHAMACOS study. Environ Health Perspect. 2015;123(6):636–42.PubMedPubMedCentral
55.
Barry V, Darrow LA, Klein M, et al. Early life perfluorooctanoic acid (PFOA) exposure and overweight and obesity risk in adulthood in a community with elevated exposure. Environ Res. 2014;132:62–9.CrossRefPubMed
56.
Halldorsson TI, Rytter D, Haug LS, et al. Prenatal exposure to perfluorooctanoate and risk of overweight at 20 years of age: a prospective cohort study. Environ Health Perspect. 2012;120(5):668–73.CrossRefPubMedPubMedCentral
57.
Ibrahim MM, Fjaere E, Lock EJ, et al. Chronic consumption of farmed salmon containing persistent organic pollutants causes insulin resistance and obesity in mice. PLoS One. 2011;6(9), e25170.CrossRefPubMedPubMedCentral
58.
Howell 3rd G, Mangum L. Exposure to bioaccumulative organochlorine compounds alters adipogenesis, fatty acid uptake, and adipokine production in NIH3T3-L1 cells. Toxicol in Vitro. 2011;25(1):394–402.CrossRefPubMed
59.
Ngo HT, Hetland RB, Sabaredzovic A, et al. In utero exposure to perfluorooctanoate (PFOA) or perfluorooctane sulfonate (PFOS) did not increase body weight or intestinal tumorigenesis in multiple intestinal neoplasia (Min/+) mice. Environ Res. 2014;132:251–63.CrossRefPubMed
Metadata
Title
Infectious and Environmental Influences on the Obesity Epidemic
Authors
Lili Huo
Jasmine Lyons
Dianna J. Magliano
Publication date
01-09-2016
Publisher
Springer US
Published in
Current Obesity Reports / Issue 3/2016
Electronic ISSN: 2162-4968
DOI
https://doi.org/10.1007/s13679-016-0224-9

Other articles of this Issue 3/2016

Current Obesity Reports 3/2016 Go to the issue

The Obesity Epidemic: Causes and Consequences (A Peeters and A Cameron, Section Editors)

The Impact of Obesity in the Workplace: a Review of Contributing Factors, Consequences and Potential Solutions

Health Services and Programs (AG Tsai, Section Editor)

Investing in Obesity Treatment: Kaiser Permanente’s Approach to Chronic Disease Management

The Obesity Epidemic: Causes and Consequences (A Peeters and A Cameron, Section Editors)

“Whole-of-Community” Obesity Prevention: A Review of Challenges and Opportunities in Multilevel, Multicomponent Interventions

Health Services and Programs (AG Tsai, Section Editor)

Obesity Treatment in the UK Health System

The Obesity Epidemic: Causes and Consequences (A Peeters and A Cameron, Section Editors)

Sleep Duration and Obesity in Adults: What Are the Connections?

Health Services and Programs (AG Tsai, Section Editor)

Obesity Treatment at HealthPartners: Adaptation of Clinical Guidelines into Systems for Practice Operations

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits